Royalty Pharma Sub-Manager, LLC

hedge fundUpdated 20 days ago

Managed by Royalty Pharma Sub-Manager, Llc • Latest filing Q2 2026

Portfolio value

$241.9M

Q2 2026

Filings

Quarterly 13F history

Top-10 concentration

100.0%

Weight of largest holdings

Annualized return

—

Implied from 13F holdings

Portfolio value history

13F-disclosed portfolio value over 3 quarters

Show data table

Period	Portfolio value
Q4 2025	$171.3M
Q1 2026	$172.8M
Q2 2026	$241.9M

Top holdings

4 positions as of Q2 2026

View filing

#	Stock	Value	Shares	% Portfolio	Change
1	C CYTK CYTOKINETICS, INC	$83.5M	980.4K	34.52%	—
2	Z ZBIO ZENAS BIOPHARMA, INC.	$60.6M	2.39M	25.05%	—
3	K KLRA KAILERA THERAPEUTICS	$54.1M	2.46M	22.36%	—
4	B BHVN BIOHAVEN LTD	$43.7M	2.94M	18.06%	—

1.CYTK

CYTOKINETICS, INC

Value

$83.5M

980.4K

% Port

34.52%

2.ZBIO

ZENAS BIOPHARMA, INC.

Value

$60.6M

2.39M

% Port

25.05%

3.KLRA

KAILERA THERAPEUTICS

Value

$54.1M

2.46M

% Port

22.36%

4.BHVN

BIOHAVEN LTD

Value

$43.7M

2.94M

% Port

18.06%

Explore

All funds Consensus buys Trending this quarter Compare portfolios What is a 13F?Filing deadlines